Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.
We report the successful use of anti-CD20 therapy in a child with refractory myasthenia gravis (MG), an antibody-mediated autoimmune disease, who did not respond to conventional therapy. After initiation of anti-CD20 therapy, clinical improvement (muscular strength, pulmonary function) was observed.
Wylam
Mark E
ME
Department of Pediatrics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. wylam.mark@mayo.edu
Anderson
Peter M
PM
Kuntz
Nancy L
NL
Rodriguez
Vilmarie
V
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D009157:Myasthenia Gravis / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab